02.09.24 -- Insights From Animals And Evolution

The Dedham Group's Jennifer Klarer, M.Sc. Eng., joins Erin Harris on this episode of Cell & Gene: The Podcast for a deep dive into pricing and value of CGTs. Klarer shares a detailed breakdown of the most misunderstood aspects of cell and gene therapy pricing, value, and affordability. She details how manufacturers can get ahead of addressing time to treatment issues typically experienced at launch. Listen now to their discussion about obtaining adequate investment dollars.

As you develop your future cell therapy drug, consider the risks and benefits of using autologous or allogeneic methods to best suit your development and manufacturing needs.

Explore how MAPPs demonstrates promise as a valuable tool for comprehensive immunogenicity assessment in therapeutic protein development, contributing to safer and more effective biologics.

Understand how the DEPICT Act not only underscores the importance of diversity in research but also sets the stage for a more inclusive and comprehensive approach to healthcare development in the U.S.

Expedited development programs require adapting to accelerated development timelines. The challenge is to build a strategy that maintains the integrity, quality, and timeliness of the manufacturing process.

The biopharmaceutical industry is trending toward building process characterization systems and processes early in a project’s life cycle, enabling success for later-stage development.